Member Info for Top.trader

Hsbc tr1 they have brought 5% of sensyne

invesco have brought 4.something% if I’m reading it right?

Could be time to fasten seatbelts

Cheers bluebelly I knew I’d seen something about it, hopefully we will get an ipo date sometime soon.

Great news, not a license just yet but for anyone looking at a jv or offtake we are now more attractive with 100% ownership. Well done BOD

I think the problem is even if it is going on the likelihood of securing a prosecution is low because these people aren’t stupid and won’t leave tracks or evidence.

This rounds up the legislation simply

https://www.stpaulschambers.com/what-is-insider-dealing/

Call me an optimist, but could we be in the quiet period after listing on nasdaq. Just been through the Argo ipo and they weren’t allowed to release news for 30 or 45 days can’t remember exactly but maybe this is what’s going on atm.

Shear class what makes you think an offer wouldn’t be made for all our shares? I highly doubt that our board alone has the capital available to take us private and keep the company running. This would suggest either a pharma company or investment bank hedge fund etc would partner with the existing board, I can’t imagine they would want existing private shareholders to be involved and therefore would make an offer to buy us out. That’s my limited knowledge though.

How do you think we could end up in a situation where we end up with shares in a non listed company?

I think we can all guess who it was quite easily after today’s rns lol

I can see why he would consider taking the company private at this level we are far too cheap everyone knows it. The question is have management been pulling strings to lower the price to a level they are comfortable an offer will be accepted.

It has always struck me with sensyne that there is always a significant price move before good or bad news, this hasn’t bothered me too much in the past because I was always holding for good news and brought more at placings. Ultimately we will find out whether the board want shareholders do receive fair value when the offer comes in.

The fact is we have a very desirable dataset which would interest many companies so there is potential for multiple offers if the board are getting us out there properly.

I hope that this is all done with good intentions however I’ve got a feeling this could be a way in which the board will buy sensyne at a cheap value in partnership with an investor and then relist in America in the future. That is a total guess mind due and I hope to see a takeover offer in £3-£5 area which I think would be realistic.

Late reported trades from 29th Oct totalling 4million quids worth. Someone is confident

Has anyone been today 2 o clock Voco Thames hotel in Oxford?

Shear class gatemore have expressed their interest to sensyne in achieving a nasdaq listing and the below rns confirms that it is something sensyne are looking at

Oxford, U.K. 19 July 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the ethical AI company, announces an update on its strategy which now includes exploring a potential dual-listing on Nasdaq amongst other options. As stated in our financial year end trading update on 27 May 2021, the Company continues to explore strategic opportunities, including making acquisitions, that leverage its organic growth and create additional shareholder value. Any decision to list in the US would complement the Company's primary listing on the AIM market of the London Stock Exchange and Sensyne remains committed to being a UK-headquartered company. Any acquisition or strategic equity partnership would be consistent with Sensyne's commitment to the ethical application of AI to patient data and its established strategic research agreements with the NHS and US health systems.

Some nice bits of info in that rns. Permits for 360000 tonnes of ore per year currently being sought to allow 1000 tpd permits will be in place before we reach the milestone. And average 9grams per tonne from east ramp. Sounds like the ship is in order

Personally I don’t think we will see another fund raise on a U.K. market. If there is an ipo on nasdaq then yes. We had plenty of cash in the bank I think 23million at April 2021 and have since signed commercial contracts. There should be more of these coming and if we do end up on the nasdaq then the fund raise will likely be outweighed by the positives of listing in America.

The pharma stocks over there can do silly multiples in a day and I think we are a unique company with a concept that doesn’t take much to grasp so the interest should be widespread if the ipo is marketed properly - I am sure the board are capable.

Cantab to be used in a schizophrenia trial with a repeat client, £600k over 3 years. Not to be sniffed at!

I like the way this company produces their rns releases, they are never cryptic with figures or information they just give you the facts and it’s all we need. Good luck

I thought perhaps we were being shorted but according to short trackers online there are no positions over 0.5% open.

Could the share price be being held down for a potential takeover? This question crossed my mind but surely confidentiality for patient data would be a very sticky situation if for instance a large pharmaceutical company were to take over. I cannot fathom how this is back at below placing level. The only blessing is the opportunity to average down.

Doubled patient record that means we should be going up 100% doesn’t it? In all seriousness it’s good to see we are moving fast in the US and working with what appear to be the best in class companies.

Sensyne Health and OMNY Health Sign Teaming Agreement to Support Breakthrough Research Through the Power of Real World Data and AI



Sensyne and OMNY will collaborate to develop new proposals to life sciences companies and healthcare providers to use real world data and advanced analytical tools to improve patient outcomes and accelerate the development of new medicines



The Teaming Agreement allows OMNY to engage Sensyne's data analytics tools and consulting services and provides Sensyne with the potential to access OMNY Health's 22 million de-identified patient records





Dover, DE and Atlanta, GA. Oxford, U.K. October 15, 2021 : Sensyne Health plc (LSE: SENS) ("Sensyne"), the ethical Clinical AI company, and OMNY Health ("OMNY"), the largest US-based real world data network, today announced a strategic teaming relationship.



The arrangement establishes a nimble framework under which Sensyne can contract for access to OMNY Health's platform of more than 22 million de-identified patient records across all therapeutic areas in support of Sensyne's data analytics work for life science companies. In addition, Sensyne and OMNY have agreed to work together on commercial projects for life science clients to advance and accelerate ethical medical research. By bringing biopharma clients a joint offering with OMNY real-world data and Sensyne machine learning expertise, both companies-and their health system partners-will have more opportunities to support important life sciences research.



The OMNY data network complements Sensyne's existing global medical research dataset of 22.1 million patients, ethically sourced through strategic partnerships with US health systems and the UK's National Health Service (NHS) trusts. With a data network that spans over 50,000 providers across 40 states, OMNY's data platform also offers control, security, and data governance to maximize the utility of information while maintaining compliance with US regulations. Sensyne will now have a new avenue to access an additional 22 million unique patient records, significantly enhancing the scale of real world data on which Sensyne can apply its advanced machine learning and bringing the combined total of de-identified patient data available for its research to over 44m patients.



Derek Baird, President, North America, Sensyne Health said:

"This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries. The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way. We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients. This is an exciting alliance, and we are thrilled to be working to

Answers incorrect show some working out please try harder or the share price will keep rising.

I imagine this is how the deramping course tutor would mark such a poor piece of work.

2 for 1 reverse consolidation. Holders will receive 1 new Tiziana share for each old Tiziana they currently hold. New Tiziana will be tradeable on nasdaq only.

Old Tiziana delisted on 21/10 and new shares will be issued 14 days later.

I assume there will be another consolidation for the ipo to get the share price high enough to list on nasdaq?

A lot of big buys wonder if there will be a notification of an institution buying in tomorrow